Looking ahead to 2026, Doustdar said Novo Nordisk had high expectations for the potential launches of new incretin ...

The loss of market exclusivity for a trio of big-selling drugs in the last quarter of 2025 dragged down Novartis sales, but ...

"The government has claimed that the deal will only cost around £1 billion per year, but the UK's new commitment to double ...

There’s no doubt that large language models and generative AI tools have taken the world by storm. Their ability to create, ...

Wave Life Sciences has lost GSK as the partner for its RNA-editing drug for alpha-1 antitrypsin deficiency (AATD), just over ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Lisa Sims, executive director of learning strategy & ...

ICH E6 (R3) introduces a dedicated section on data governance, reflecting the increasing complexity of data sources and ...

Novo Nordisk is considering additional regulatory filings for CagriSema – already submitted in the US for obesity – after the drug outperformed Ozempic in a head-to-head diabetes study.

Two months later, the institute launched the Standardized Organoid Modeling Center, a national initiative financed with an initial commitment of $87 million over three years, intended to improve the ...

Almost 30,000 people in England with chronic obstructive pulmonary disease (COPD) could soon have access to a biologic treatment, Sanofi and Regeneron's Dupixent, after it was recommended for use by ...

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp increase on ...

GSK has moved to shore up its R&D pipeline with a strategic-level deal with China's Jiangsu Hengrui Pharma that spans a dozen drug candidates and could be worth up to $12.5 billion. The wide-ranging ...